146724-94-9 br Joint preanalytical QC analysis of
Joint preanalytical QC analysis of DNA and RNA offered additional insights into the quality distinctions between analytes and specimen types. As expected, FFPE surgical resections were of the highest quality, with 100% of specimens yielding sufficient DNA and RNA for NGS analyses. In contrast, 99% and 86% of CNB specimens offered sufficient material for DNA and RNA NGS analyses, respectively. At the extreme end of the quality spectrum were the FNA smears with 48% and 2% pass rates for DNA and RNA, respectively. Across this continuum of quality, we noticed a general trend with respect to the suitability of a specimen's DNA relative to RNA, namely, that specimens were more likely to offer sufficient DNA for analysis. A parallel and related observation was that analysis of RNA 146724-94-9 trends (analysis of immune checkpoint inhibitor expression markers and CNAs) tended to show more robust associations in the FFPE surgical resections relative to CNBs.
The longer-term rationale for a conjoined analysis of DNA and RNA is to provide a foundation for integrative, targeted NGS applications that pair genotype with molecular phenotype in order to interpret variants of unknown significance through orthogonal functional evidence. In this paradigm, RNA expression can be viewed as a molecular information bottleneck that can aid in the interpretation of the long tail of genetic and epigenetic variation that underlies tumor evolution. Functional pathway analysis will enable the resolution of cryptic and latent oncogenic driver mutations and shed light onto the “dark matter” that underlies cancer. The NGS workflow presented here offers a foundation for integrative analysis of DNA and RNA compatible with a range of clinical specimen types in a small-footprint format suitable for routine diagnostic and clinical research purposes to enable holistic interpretation of cancer specimens.
B. C. H., R. A. B., R. D. C., R. Z., S. G., J. R. T., L. C., and G. J. L. were employed by Asuragen, Inc., at the time that the research was performed. Asuragen employees have or may have stock in Asuragen, Inc. Asuragen markets a for Research Use Only (RUO) test for QuantideX® NGS RNA Lung Cancer Kit as a clinical research tool enabling the simultaneous assessment of biomarkers frequently observed in lung cancer and QuantideX® NGS DNA Hotspot 21 Kit (RUO), a research tool that interrogates hotspot regions within 21 genes that are commonly mutated in a number of solid and hematological malignancies.
The authors thank Annette Schlageter for assistance with the manuscript.
 Pant S, Weiner R, and Marton MJ (2014). Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays
844 An Integrated Next-Generation Sequencing System Haynes et al. Translational Oncology Vol. 12, No. 6, 2019
 Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, and Kris MG, et al (2015). Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alter-ations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 21, 3631–3639. http://dx.doi. org/10.1158/1078-0432.CCR-14-2683.
 Oliveira DM, Mirante T, Mignogna C, Scrima M, Migliozzi S, Rocco G, Franco R, Corcione F, Viglietto G, and Malanga D, et al (2018). Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. Oncotarget 9, 22749–22768. http://dx.doi.org/10.18632/ oncotarget.25229.
 Sah S, Chen L, Houghton J, Kemppainen J, Marko AC, Zeigler R, and Latham GJ (2013). Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med 5, 1. http://dx.doi.org/10.1186/gm481.  Houghton J, Hadd AG, Zeigler R, Haynes BC, and Latham GJ (2016). Integration of wet and dry bench processes optimizes targeted next-generation sequencing of low-quality and low-quantity tumor biopsies. J Vis Exp , 1–13. http://dx.doi.org/10.3791/53836.
Translational Oncology Vol. 12, No. 6, 2019 An Integrated Next-Generation Sequencing System Haynes et al. 845
 Baldi L, Mengoli MC, Bisagni A, Banzi MC, Boni C, and Rossi G (2014). Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung Cancer 86, 291–295. http://dx.doi.org/10.1016/j.lungcan.2014.09.011.
Contents lists available at ScienceDirect
Journal of Geriatric Oncology
An international comparison of treatment and short-term overall survival for older patients with pancreatic cancer